accountregulatory filings and marketing approval in North America and Europe for tivozanib as a monotherapy in first-line renal cell carcinoma (RCC), as well as more than $780 million in commercial milestones. In addition to the ongoing Phase 3 TIVO-1 trial and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to AVEO Reports First Quarter 2011 Accomplishments And Financial Results
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account